{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:25:02Z","timestamp":1793654702935,"version":"4.5.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.rmed.2023.107362","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T23:08:31Z","timestamp":1689203311000},"page":"107362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy"],"prefix":"10.1016","volume":"217","author":[{"given":"R.H.","family":"Sansores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ram\u00edrez-Venegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Montiel-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dom\u00ednguez-Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"Alva-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Falf\u00e1n-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"P\u00e9rez-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Olaya-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.O.","family":"Zavaleta-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aguilar-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Escobar-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Poo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"M.","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2023.107362_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMcp2009575","article-title":"Severe covid-19","volume":"383","author":"Berlin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2023.107362_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95565-8","article-title":"More than 50 long-term effects of COVID-19: a systematic review and meta-analysis","volume":"11","author":"Lopez-Leon","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2023.107362_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and their impact","volume":"38","author":"Davis","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.rmed.2023.107362_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"Persistent symptoms in patients after acute COVID-19","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2023.107362_bib5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.15585\/mmwr.mm6930e1","article-title":"Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020","volume":"69","author":"Tenforde","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.rmed.2023.107362_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.rmed.2023.107362_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/14799731211002240","article-title":"Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"18","author":"Cares-Marambio","year":"2021","journal-title":"Chron. Respir. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2023.107362_bib8","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3390\/jcm9061917","article-title":"COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection","volume":"9","author":"Lechowicz","year":"2020","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.rmed.2023.107362_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1515\/cclm-2021-1021","article-title":"The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors","volume":"60","author":"Vianello","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107362_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12931-022-02163-x","article-title":"Pulmonary function and chest computed tomography abnormalities 6-12 months after recovery from COVID-19: a systematic review and meta-analysis","volume":"23","author":"Lee","year":"2022","journal-title":"Respir. Res."},{"issue":"162","key":"10.1016\/j.rmed.2023.107362_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0194-2021","article-title":"Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection","volume":"30","author":"Mylvaganam","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2023.107362_bib12","article-title":"Post COVID-19 pulmonary fibrosis; a meta-analysis study","volume":"77","author":"Hama Amin","year":"2022","journal-title":"Ann Med Surg (Lond)."},{"key":"10.1016\/j.rmed.2023.107362_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijid.2021.05.055","article-title":"Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: an interventional study","volume":"108","author":"Umemura","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2023.107362_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.rmed.2023.107362_bib15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1021\/acs.molpharmaceut.2c00052","article-title":"Investigating the role of the reduced solubility of the pirfenidone-fumaric acid cocrystal in sustaining the release rate from its tablet dosage form by conducting comparative bioavailability study in healthy human volunteers","volume":"19","author":"Kumari","year":"2022","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.rmed.2023.107362_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05279","article-title":"Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis","volume":"6","author":"Barranco-Gardu\u00f1o","year":"2020","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.rmed.2023.107362_bib18","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10787-022-01027-6","article-title":"Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals","volume":"30","author":"Al-Kuraishy","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.rmed.2023.107362_bib19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1148\/radiol.2363040958","article-title":"Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT","volume":"236","author":"Chang","year":"2005","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.rmed.2023.107362_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/thx.2006.061648","article-title":"Standardisation of lung function testing: helpful guidance from the ATS\/ERS Task Force","volume":"61","author":"Laszlo","year":"2006","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.rmed.2023.107362_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1157\/13090581","article-title":"Valores de referencia espirom\u00e9trica en 5 grandes ciudades de Latinoam\u00e9rica para sujetos de 40 o m\u00e1s a\u00f1os de edad [Spirometric reference values in 5 large Latin American cities for subjects aged 40 years or over]","volume":"42","author":"P\u00e9rez-Padilla","year":"2006","journal-title":"Arch. Bronconeumol."},{"issue":"1","key":"10.1016\/j.rmed.2023.107362_bib22","article-title":"2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung [published correction appears in Eur Respir J. 2018 Nov 22;52(5):]","volume":"49","author":"Graham","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.rmed.2023.107362_bib23","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4187\/respcare.04590","article-title":"Reference values for the diffusing capacity determined by the single-breath technique at different altitudes: the Latin American single-breath diffusing capacity reference project","volume":"61","author":"V\u00e1zquez-Garc\u00eda","year":"2016","journal-title":"Respir. Care"},{"issue":"6","key":"10.1016\/j.rmed.2023.107362_bib24","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1183\/09031936.00150314","article-title":"An official European Respiratory Society\/American Thoracic Society technical standard: field walking tests in chronic respiratory disease","volume":"44","author":"Holland","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2023.107362_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2017","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","volume":"26","author":"Lancaster","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2023.107362_bib26","first-page":"A2695","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis in a US expanded access program","volume":"193","author":"Lancaster","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"135","key":"10.1016\/j.rmed.2023.107362_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1183\/09059180.00011514","article-title":"Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis","volume":"24","author":"Cottin","year":"2015","journal-title":"Eur. Respir. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2023.107362_bib28","first-page":"109","article-title":"Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"35","author":"Boonpheng","year":"2018","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"2","key":"10.1016\/j.rmed.2023.107362_bib29","doi-asserted-by":"crossref","first-page":"E70","DOI":"10.1148\/radiol.2020203557","article-title":"Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis","volume":"298","author":"Suh","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.rmed.2023.107362_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100284","article-title":"Pulmonary embolism and deep venous thrombosis after COVID-19: long-term risk in a population-based cohort study","author":"Sjoland","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rmed.2023.107362_bib31","article-title":"Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study","volume":"377","author":"Katsoularis","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.rmed.2023.107362_bib32","first-page":"389","article-title":"Post-COVID interstitial lung disease - the tip of the iceberg","volume":"43","author":"Kewalramani","year":"2023","journal-title":"Immunol. Allergy Clin."},{"issue":"3","key":"10.1016\/j.rmed.2023.107362_bib33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/CM9.0000000000001614","article-title":"A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019","volume":"135","author":"Zhang","year":"2021","journal-title":"Chin Med J (Engl)."},{"issue":"2","key":"10.1016\/j.rmed.2023.107362_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/14782715221103402","article-title":"Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: a single-centre study","volume":"52","author":"Singh","year":"2022","journal-title":"J R Coll Physicians Edinb"},{"issue":"12","key":"10.1016\/j.rmed.2023.107362_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14961","article-title":"Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography","volume":"75","author":"Acat","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"10.1016\/j.rmed.2023.107362_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/cmrp.cmrp_110_21","article-title":"Early intervention with anti-fibrotic pirfenidone is effective than corticosteroids in preventing pulmonary fibrosis in severe COVID pneumonia patients","volume":"12","author":"Tanvir","year":"2022","journal-title":"Curr Med Res Pract"},{"key":"10.1016\/j.rmed.2023.107362_bib37","first-page":"A4046","article-title":"Pirfenidone for COVID-19 associated pulmonary fibrosis: a case series [abstract]","volume":"205","author":"Co","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107362_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"10.1016\/j.rmed.2023.107362_bib39","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1164\/rccm.201702-0400PP","article-title":"A standardized diagnostic ontology for fibrotic interstitial lung disease. An international working group perspective","volume":"196","author":"Ryerson","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.rmed.2023.107362_bib40","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.21037\/jtd-20-1363","article-title":"Evolution of chest CT manifestations of COVID-19: a longitudinal study","volume":"12","author":"Kong","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.rmed.2023.107362_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/lungindia.lungindia_659_21","article-title":"Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: a review of literature and report from an expert working group","volume":"39","author":"Salvi","year":"2022","journal-title":"Lung India"},{"issue":"1","key":"10.1016\/j.rmed.2023.107362_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s42399-022-01140-1","article-title":"Evolution of COVID-19 pulmonary fibrosis-like residual changes over time - longitudinal chest CT up to 9 months after disease onset: a single-center case series","volume":"4","author":"Poerio","year":"2022","journal-title":"SN Compr Clin Med"},{"issue":"6","key":"10.1016\/j.rmed.2023.107362_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1164\/rccm.202203-0564OC","article-title":"Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post-COVID-19 study","volume":"207","author":"Stewart","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.rmed.2023.107362_bib44","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1513\/AnnalsATS.202004-324OC","article-title":"Chest computed tomography and clinical follow-up of discharged patients with COVID-19 in Wenzhou City, Zhejiang, China","volume":"17","author":"Liu","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.rmed.2023.107362_bib45","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/thoraxjnl-2021-217031","article-title":"Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length","volume":"76","author":"McGroder","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2023.107362_bib46","series-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"1","key":"10.1016\/j.rmed.2023.107362_bib47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol. Bull."},{"issue":"9","key":"10.1016\/j.rmed.2023.107362_bib48","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/jpm11090838","article-title":"Long COVID-19 pulmonary sequelae and management considerations","volume":"11","author":"Boutou","year":"2021","journal-title":"J. Personalized Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123002500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123002500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:33:55Z","timestamp":1760618035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611123002500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":47,"alternative-id":["S0954611123002500"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107362","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107362"}}